Actuate Therapeutics (ACTU) Income towards Parent Company (2023 - 2025)

Actuate Therapeutics (ACTU) has reported Income towards Parent Company for 3 consecutive years, with -$4.6 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Income towards Parent Company rose 27.92% year-over-year to -$4.6 million; the TTM figure through Dec 2025 stood at -$22.3 million (up 10.53% YoY), while the FY2025 annual figure was -$23.9 million, up 61.89% from the prior year.
• Income towards Parent Company climbed to -$4.6 million in Q4 2025 per ACTU's latest filing, from -$5.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$4.6 million in Q4 2025 and bottomed at -$7.8 million in Q1 2024.
• Historically, Income towards Parent Company has averaged -$6.1 million across 3 years, with a median of -$5.9 million in 2025.
• On a YoY basis, Income towards Parent Company climbed as much as 27.92% in 2025 and fell as far as 9.53% in 2025.
• Actuate Therapeutics' Income towards Parent Company stood at -$7.6 million in 2023, then advanced by 15.5% to -$6.4 million in 2024, then grew by 27.92% to -$4.6 million in 2025.
• Business Quant data shows ACTU's Income towards Parent Company at -$4.6 million in Q4 2025, -$5.4 million in Q3 2025, and -$5.9 million in Q2 2025.